Your browser doesn't support javascript.
loading
Novel TGF-ß inhibitors ready for prime time in onco-immunology.
de Gramont, Armand; Faivre, Sandrine; Raymond, Eric.
Afiliação
  • de Gramont A; AFR Oncology, Boulogne-Billancourt , France.
  • Faivre S; Medical Oncology, Hôpitaux Universitaires Paris Nord Val de Seine (HUPVNS), Université Paris 7 , Paris, France.
  • Raymond E; Medical Oncology, Groupe Hospitalier Paris Saint-Joseph , Paris, France.
Oncoimmunology ; 6(1): e1257453, 2017.
Article em En | MEDLINE | ID: mdl-28197376
ABSTRACT
Transforming Growth Factor (TGF)-ß inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article